Sourcing GMP-Grade Peptides for Phase I Trials: A Practical Guide
A systematic framework for qualifying peptide CDMOs for first-in-human studies, covering vendor audit criteria, Certificate of Analysis requirements, and ICH Q7-aligned quality agreements.
Why GMP-Grade Peptide Sourcing Is a Critical Path Activity
First-in-human (FIH) clinical programmes depend on reliable access to peptide APIs that meet EU GMP standards. Delays or quality failures at the drug substance level can halt an entire programme. Selecting and qualifying the right peptide CDMO early — ideally before IND filing — is therefore a strategic as well as operational decision.
Vendor Qualification Framework
A robust vendor qualification process should encompass four pillars: (1) facility audits against EU GMP Annex 11 and ICH Q7, (2) analytical capability assessment for peptide characterisation, (3) regulatory inspection history and EMA DMF filing experience, and (4) supply chain transparency including starting material traceability.
Certificate of Analysis Requirements
At minimum, CoA documentation for GMP-grade peptides should include: HPLC purity ≥98% (or per specification), mass spectrometry identity confirmation, amino acid analysis, moisture content by Karl Fischer titration, residual solvent profiles to ICH Q3C, and — for parenteral preparations — bioburden and bacterial endotoxin testing.
Quality Agreements Under ICH Q7
ICH Q7 Section 16 requires written quality agreements between API manufacturers and their contract service providers. Key provisions should address change control notification timelines, deviation reporting thresholds, access rights for customer audits, and annual product review obligations.
Dual-Source Strategy
For clinical-stage peptide programmes, maintaining a qualified backup supplier reduces supply chain risk significantly. While dual-sourcing adds qualification overhead, the investment is typically justified from Phase II onward where commercial supply continuity becomes critical.
Conclusion
Qualified peptide CDMO selection requires systematic effort across technical, quality, and commercial dimensions. Engaging the ViraChem platform at virachemical.com provides access to pre-qualified EU peptide CDMOs with verified GMP credentials and regulatory track records.